BPTSY.US Biophytis S.A.

Healthcare Biotechnology USA Stocks
0.5000 USD
Close of Nov 14, 2026
0.0010 2.00
Market cap
USD 19.2M
P/E
-
P/B
2.60x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2025.

Is BPTSY.US undervalued?

Graham number

The Graham number of Biophytis S.A. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biophytis S.A. fundamental analysis

No fundamental analysis for Biophytis S.A. yet.

Biophytis S.A. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biophytis S.A.

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients with age-related diseases. The company's lead drug candidate is the BIO101 to treat obesity, respiratory infections due to Covid-19, sarcopenia, and Duchenne Muscular Dystrophy (DMD). It has a collaboration agreement with AFM-Telethon for the development of its BIO101 for the treatment of DMD. It …

Full company profile